Intelligent Bio Solutions Inc. INBS

Q4 FY2026 · ended Jun 30, 2026 · Revenue $1.15M, +35.8% YoY · Filed Aug 19, 2026

Intelligent Bio Solutions Inc. (INBS) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In Q4 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $1.1 million and a net loss of $3.9 million. Free cash flow was -$3.2 million. As of Jun 30, 2026 it held $4.0 million in cash and investments and $1.8 million in total debt.

Revenue
$1.15M
+35.8% vs year-ago quarter
Net income
$-3.91M
-26.5% vs year-ago quarter
Operating cash flow
$-3.18M
-44.0% vs year-ago quarter
Free cash flow
$-3.18M
+26.7% vs prior quarter
EPS
$-1.56
+64.6% vs year-ago quarter
Dividend per share
None
Shares outstanding
3.03M
-66.3% vs year-ago quarter
Net cash
$2.17M
Q4 FY2026
Operating margin
-346.4%
Q4 FY2026

Company profile

Industry
Surgical & Medical Instruments & Apparatus (SIC 3841)
Listed as
INBS (Nasdaq)
Fiscal year ends
June 30
Incorporated in
DE
Headquarters
New York, NY
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1725430
Former names
GBS Inc. (until Oct 18, 2022); Glucose Biosensor Systems (Greater China) Holdings, Inc. (until Sep 19, 2019)

Other Surgical & Medical Instruments & Apparatus companies

Key figures

Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.

Line
Q4 FY2026
Jun 30, 2026
Q3 FY2026
Mar 31, 2026
Q2 FY2026
Dec 31, 2025
Q1 FY2026
Sep 30, 2025
Q4 FY2025
Jun 30, 2025
Revenue
$1.1M
$1.1M
$896,774
$1.1M
$843,884
Operating income
-$4.0M
-$2.9M
-$2.6M
-$3.0M
-$3.1M
Net income
-$3.9M
-$2.9M
-$2.7M
-$3.0M
-$3.1M
Diluted EPS
-$1.56
-$1.80
-$2.82
-$0.35
-$4.42
Operating cash flow
-$3.2M
-$4.3M
-$1.6M
-$2.8M
-$2.2M
Free cash flow
-$3.2M
-$4.3M
-$1.6M
-$2.9M
—
Total assets
$11.9M
$14.9M
$17.7M
$10.0M
$8.2M
Total liabilities
$6.7M
$6.1M
$6.8M
$6.6M
$5.4M
Stockholders' equity
$5.5M
$9.0M
$11.1M
$3.6M
$3.0M
Cash and investments
$4.0M
$6.9M
$740,371
$1.7M
$1.0M
Total debt
$1.8M
$1.8M
$1.9M
$1.8M
$84,659

Recent SEC filings

Recent SEC filings
Form Description Filed Period
ARS Annual report to shareholders Nov 2, 2026 Jun 30, 2026
10-K/A Amended annual report Oct 21, 2026 Jun 30, 2026
8-K Current report
Bylaw or fiscal year change, Regulation FD disclosure
Oct 13, 2026 Oct 12, 2026
8-K Current report
Other events
Sep 11, 2026 Sep 10, 2026
8-K Current report
Regulation FD disclosure, Other events
Sep 9, 2026 Sep 9, 2026
8-K Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
Sep 2, 2026 Aug 31, 2026

Source: SEC EDGAR filings. This is company-reported data, not investment advice.